Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Start with the bone-builder, not the bisphosphonate. Experts say most osteoporosis patients get the best bone density gains when anabolic drugs are prescribed first — yet bisphosphonates remain the default in real-world practice. The gap between evidence and prescribing habits, plus low treatment rates overall, is leaving many high-risk patients underprotected.
When it comes to osteoporosis, the order in which drugs are prescribed matters — a lot. Experts increasingly agree that starting high-risk patients on anabolic agents (like romosozumab or teriparatide) before antiresorptive drugs like bisphosphonates leads to significantly greater bone mineral density (BMD) gains. The problem? Most patients in the real world still get a bisphosphonate first, partly due to insurer mandates, guideline disagreements, and the logistical hurdles of injectable anabolic therapies.
The evidence is stacking up: a 2026 review of 37 studies found anabolic-first sequences outperform bisphosphonate-first approaches, and multiple trials confirm that prior bisphosphonate use blunts the effectiveness of more potent drugs down the line. Meanwhile, guidelines remain fragmented — the American College of Physicians still recommends bisphosphonates as first-line, while a 2024 ASBMR/BHOF position statement pushes for individualized, risk-based treatment selection.
Key Takeaways:
Why it matters: With osteoporosis fractures carrying serious morbidity and mortality risks, getting the treatment sequence right — and getting patients on treatment at all — is a critical and underaddressed clinical priority.